Xin Nakanishi
Director/Board Member bei ONCTERNAL THERAPEUTICS, INC.
Vermögen: 936 $ am 31.03.2024
Profil
Xin Nakanishi is the founder of Sunvita Therapeutics, LLC, which was founded in 2009.
She served as the Chief Executive Officer from 2009 to 2018.
Currently, she is the Chief Executive Officer at Shanghai Pharma Biotherapeutics Usa, Inc. and an Independent Director at Oncternal Therapeutics, Inc. She previously worked as the Biology Director at Phenomix Corp.
and Director at Oncternal Oncology, Inc. She also served as a Venture Partner at Yuansheng Bioventure, Inc. from 2017 to 2018.
Dr. Nakanishi received her undergraduate degree from Wuhan University and her doctorate from the University of Kansas.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
28.06.2023 | 104 ( 0,00% ) | 936 $ | 31.03.2024 |
Aktive Positionen von Xin Nakanishi
Unternehmen | Position | Beginn |
---|---|---|
ONCTERNAL THERAPEUTICS, INC. | Director/Board Member | 01.11.2018 |
Shanghai Pharma Biotherapeutics Usa, Inc. | Chief Executive Officer | 01.07.2018 |
Ehemalige bekannte Positionen von Xin Nakanishi
Unternehmen | Position | Ende |
---|---|---|
Sunvita Therapeutics, LLC | Chief Executive Officer | 01.01.2018 |
Yuansheng Bioventure, Inc. | Corporate Officer/Principal | 01.01.2018 |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Corporate Officer/Principal | - |
Oncternal Oncology, Inc.
Oncternal Oncology, Inc. Pharmaceuticals: MajorHealth Technology Oncternal Oncology, Inc. is a clinical-stage oncology company, which engages in the development of novel therapies for both rare and common cancers. The company was founded by Lauren Otsuki and Cam L. Garner and is headquartered in San Diego, CA. | Director/Board Member | - |
Ausbildung von Xin Nakanishi
Wuhan University | Undergraduate Degree |
University of Kansas | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ONCTERNAL THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Health Technology |
Oncternal Oncology, Inc.
Oncternal Oncology, Inc. Pharmaceuticals: MajorHealth Technology Oncternal Oncology, Inc. is a clinical-stage oncology company, which engages in the development of novel therapies for both rare and common cancers. The company was founded by Lauren Otsuki and Cam L. Garner and is headquartered in San Diego, CA. | Health Technology |
Shanghai Pharma Biotherapeutics Usa, Inc. | |
Yuansheng Bioventure, Inc. | |
Sunvita Therapeutics, LLC |